Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06781437

Retrospective Observational Study of Italian Cohort of Lymphoma Patients (RETRO-LYMPH)

observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

observational, non-interventional, retrospective, single-center study focusing on patients with lymphoma / lymphoproliferative syndrome between January 1980 and September 2021.

Study objectives are to enrich the data on the prognostic role of clinical and epidemiological factors associated with clinical and epidemiological data of patients;

  • to identify the factors that affect the evolution of the disease, such as lifestyle and occupational factors, as well as the type of treatment;
  • to provide a platform for future research projects;
  • Description of the various therapies that have occurred over time, duration of treatment, causes of interruption of treatment, responses;
  • Description of the adverse events / safety of the various therapies for lymphoma and lymphoproliferative syndromes;
  • Patient survival. Descriptive analyses will be conducted by tabulating frequency distributions and percentages and mean and median values, standard deviations, quartiles and extreme values for continuous variables. Progression-free survival, disease-free survival and overall survival will be examined using Kaplan-Meier point estimates

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age greater than or equal to 18 years of enrollment
  • Diagnosis of lymphoma or lymphoproliferative syndrome between January 1980 and September 2021
  • Signature of the informed consent form where applicable

Exclusion criteria

  • none

Treatment and study plan

Primary outcomes

  1. Incidence and prevalence of lymphomas/lymphoproliferative syndromes referred to the Centre between January 1980 and September 2021

    Time frame: through study completion, an average of 6 years

    Incidence and prevalence

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: through study completion, an average of 6 years

    Overall Survival (OS)

  2. event free survival (EFS)

    Time frame: through study completion, an average of 6 years

    event free survival (EFS)

  3. Lymphoma specific survival (LSS)

    Time frame: through study completion, an average of 6 years

    Lymphoma specific survival (LSS)

  4. Progression Free Survival (PFS)

    Time frame: through study completion, an average of 6 years

    Progression Free Survival (PFS)

  5. Net survival (5 years)

    Time frame: through study completion, an average of 6 years

    Net survival

  6. Response rate (5 years)

    Time frame: through study completion, an average of 6 years

    Response rate

  7. Duration of Response (DoR)

    Time frame: through study completion, an average of 6 years

    Duration of Response (DoR)

  8. time to next anti-lymphoma treatment (TTNLT)

    Time frame: through study completion, an average of 6 years

    time to next anti-lymphoma treatment (TTNLT)

  9. Duration of survival after progression

    Time frame: through study completion, an average of 6 years

    Duration of survival after progression

  10. lymphoma transformation frequency

    Time frame: through study completion, an average of 6 years

    lymphoma transformation frequency

  11. Frequency of secondary neoplasy

    Time frame: through study completion, an average of 6 years

    Frequency of secondary neoplasy

  12. frequency of other chronic diseases

    Time frame: through study completion, an average of 6 years

    frequency of other chronic diseases

Study contacts

Contact information is provided by the study sponsor or research team.

Alessandro Broccoli, MD

CONTACT

[email protected]

+390512143680

Pier Luigi Zinzani, MD

CONTACT

[email protected]

+390512143680

Sponsors and collaborators

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Other

Registry information

Official study title

Studio Osservazionale Retrospettivo Di Coorte Italiana Di Pazienti Con Linfoma (RETRO-LYMPH)

Acronym: RETRO-LYMPH

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Jan 17, 2025
Registry last updated
Jan 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.